206 related articles for article (PubMed ID: 27384490)
1. Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells.
Kitahata Y; Kanuma T; Hayashi M; Kobayashi N; Ozasa K; Kusakabe T; Temizoz B; Kuroda E; Yamaue H; Coban C; Yamamoto T; Kobiyama K; Aoshi T; Ishii KJ
Oncotarget; 2016 Aug; 7(31):48860-48869. PubMed ID: 27384490
[TBL] [Abstract][Full Text] [Related]
2. Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist.
Kobiyama K; Aoshi T; Narita H; Kuroda E; Hayashi M; Tetsutani K; Koyama S; Mochizuki S; Sakurai K; Katakai Y; Yasutomi Y; Saijo S; Iwakura Y; Akira S; Coban C; Ishii KJ
Proc Natl Acad Sci U S A; 2014 Feb; 111(8):3086-91. PubMed ID: 24516163
[TBL] [Abstract][Full Text] [Related]
3. Species-dependent role of type I IFNs and IL-12 in the CTL response induced by humanized CpG complexed with β-glucan.
Kobiyama K; Temizoz B; Kanuma T; Ozasa K; Momota M; Yamamoto T; Aoshi T; Kuroda E; Ishii KJ
Eur J Immunol; 2016 May; 46(5):1142-51. PubMed ID: 26786557
[TBL] [Abstract][Full Text] [Related]
4. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
Temizoz B; Kuroda E; Ohata K; Jounai N; Ozasa K; Kobiyama K; Aoshi T; Ishii KJ
Eur J Immunol; 2015 Apr; 45(4):1159-69. PubMed ID: 25529558
[TBL] [Abstract][Full Text] [Related]
5. An Antigen-Free, Plasmacytoid Dendritic Cell-Targeting Immunotherapy To Bolster Memory CD8
Masuta Y; Yamamoto T; Natsume-Kitatani Y; Kanuma T; Moriishi E; Kobiyama K; Mizuguchi K; Yasutomi Y; Ishii KJ
J Immunol; 2018 Mar; 200(6):2067-2075. PubMed ID: 29431693
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Therapeutic Efficacy of Immunostimulatory CpG-ODN by Silencing SOCS-1 with Polysaccharide/miR-155 Complexes.
Sumiya K; Izumi H; Sakurai K
ACS Appl Bio Mater; 2023 Feb; 6(2):774-783. PubMed ID: 36632777
[TBL] [Abstract][Full Text] [Related]
7. A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection.
Yamamoto T; Masuta Y; Momota M; Kanekiyo M; Kanuma T; Takahama S; Moriishi E; Yasutomi Y; Saito T; Graham BS; Takahashi Y; Ishii KJ
Int Immunol; 2019 Feb; 31(2):81-90. PubMed ID: 30535055
[TBL] [Abstract][Full Text] [Related]
8. Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
Mochizuki S; Morishita H; Kobiyama K; Aoshi T; Ishii KJ; Sakurai K
J Control Release; 2015 Dec; 220(Pt A):495-502. PubMed ID: 26562685
[TBL] [Abstract][Full Text] [Related]
9. Repolarization of glioblastoma macrophage cells using non-agonistic Dectin-1 ligand encapsulating TLR-9 agonist: plausible role in regenerative medicine against brain tumor.
Tiwari RK; Singh S; Gupta CL; Pandey P; Singh VK; Sayyed U; Shekh R; Bajpai P
Int J Neurosci; 2021 Jun; 131(6):591-598. PubMed ID: 32250189
[TBL] [Abstract][Full Text] [Related]
10. Leishmanial CpG DNA nanovesicles: A propitious prophylactic approach against visceral leishmaniasis.
Tiwari RK; Chandrakar P; Gupta CL; Sayyed U; Shekh R; Bajpai P
Int Immunopharmacol; 2021 Jan; 90():107181. PubMed ID: 33249044
[TBL] [Abstract][Full Text] [Related]
11. Induction of humoral and cellular immune response to hepatitis B virus (HBV) vaccine can be upregulated by CpG oligonucleotides complexed with Dectin-1 ligand.
Ito H; Ando T; Nakamura M; Ishida H; Kanbe A; Kobiyama K; Yamamoto T; Ishii KJ; Hara A; Seishima M; Ishikawa T
J Viral Hepat; 2017 Feb; 24(2):155-162. PubMed ID: 27807909
[TBL] [Abstract][Full Text] [Related]
12. In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy.
Okada H; Takahashi K; Yaku H; Kobiyama K; Iwaisako K; Zhao X; Shiokawa M; Uza N; Kodama Y; Ishii KJ; Seno H
Sci Rep; 2022 Feb; 12(1):2132. PubMed ID: 35136110
[TBL] [Abstract][Full Text] [Related]
13. Soluble β-glucan from Grifola frondosa induces tumor regression in synergy with TLR9 agonist via dendritic cell-mediated immunity.
Masuda Y; Nawa D; Nakayama Y; Konishi M; Nanba H
J Leukoc Biol; 2015 Dec; 98(6):1015-25. PubMed ID: 26297795
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.
Wang S; Campos J; Gallotta M; Gong M; Crain C; Naik E; Coffman RL; Guiducci C
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):E7240-E7249. PubMed ID: 27799536
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.
Karan D; Krieg AM; Lubaroff DM
Int J Cancer; 2007 Oct; 121(7):1520-8. PubMed ID: 17565748
[TBL] [Abstract][Full Text] [Related]
16. DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination.
Hayashi T; Momota M; Kuroda E; Kusakabe T; Kobari S; Makisaka K; Ohno Y; Suzuki Y; Nakagawa F; Lee MSJ; Coban C; Onodera R; Higashi T; Motoyama K; Ishii KJ; Arima H
Front Immunol; 2018; 9():2619. PubMed ID: 30515151
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
18. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
[TBL] [Abstract][Full Text] [Related]
19. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
Roda JM; Parihar R; Carson WE
J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
[TBL] [Abstract][Full Text] [Related]
20. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
